GSK is investing $100 million at its manufacturing site in Hamilton, Montana to expand the production capacity of key components used in several of its vaccines.
This includes Shingrix, which was approved by the US FDA back in 2017.
The Hamilton vaccines facility currently manufactures components of GSK’s essential adjuvant technologies, which this investment will expand further.
“For more than a decade, our Hamilton facility has supported GSK’s adjuvant system development program,” said Jack Bailey, President, US Pharmaceuticals, GSK.
“By expanding the adjuvant system production capabilities in Hamilton, we will continue to deliver long-term and sustainable supply for key vaccines, including SHINGRIX.”